Short Interest in CapsoVision, Inc. (NASDAQ:CV) Declines By 57.4%

CapsoVision, Inc. (NASDAQ:CV) was the target of a large drop in short interest in January. As of January 15th, there was short interest totaling 93,892 shares, a drop of 57.4% from the December 31st total of 220,233 shares. Based on an average daily trading volume, of 536,493 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 536,493 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CV. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research report on Friday, November 14th. Wall Street Zen raised CapsoVision to a “hold” rating in a research report on Saturday, January 10th. Roth Mkm set a $7.00 price target on CapsoVision in a research report on Tuesday, November 4th. Zacks Research upgraded CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.00.

CapsoVision Stock Down 2.3%

Shares of CapsoVision stock traded down $0.12 on Thursday, reaching $5.14. The stock had a trading volume of 130,834 shares, compared to its average volume of 512,217. The stock has a market capitalization of $240.76 million and a P/E ratio of -2.35. The company has a 50 day moving average price of $8.45 and a 200 day moving average price of $5.84. CapsoVision has a 1 year low of $3.43 and a 1 year high of $15.37.

CapsoVision (NASDAQ:CV) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $3.54 million during the quarter.

Institutional Trading of CapsoVision

An institutional investor recently bought a new position in CapsoVision stock. Citadel Advisors LLC acquired a new stake in CapsoVision, Inc. (NASDAQ:CV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned 0.05% of CapsoVision as of its most recent SEC filing.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.